Combining iPSC derived effector cell types for immunotherapy use
AssigneeFate Therapeutics, Inc.
InventorsBahram Valamehr, Jode Goodridge, Ryan Bjordahl
Life of this patent
Estimating the term…
Abstract
Provided are methods and compositions for obtaining functionally enhanced derivative effector cells obtained from directed differentiation of genomically engineered iPSCs. The derivative cells provided herein have stable and functional genome editing that delivers improved or enhanced therapeutic effects. Also provided are therapeutic compositions and the use thereof comprising the functionally enhanced derivative effector cells alone, or with antibodies or checkpoint inhibitors or additional cells in combination therapies.
Claims40
A composition comprising two or more synthetic cell populations, wherein the composition comprises:
- (i) a first synthetic cell population comprising iPSC-derived NK cells, wherein the iPSC-derived NK cells comprise:
- (a) an exogenous CD16;
- and
- (b) a first chimeric antigen receptor (CAR);
- and
- (ii) a second synthetic cell population comprising iPSC-derived T cells, wherein the iPSC-derived T cells comprise:
- at least a second chimeric antigen receptor (CAR), and wherein the second CAR is expressed under control of an endogenous promoter of a TCR locus.
Dependencies are inferred from the claim text.